Lv31
324 积分 2024-10-23 加入
Discovery of Pyrazolo[1,5-a]-1,3,5-Triazine Derivatives as Potent, Highly Selective and Orally Available Macrocyclic CDK7 Inhibitors
2小时前
已完结
Piperazinotriazole-based NK3R antagonists: Rational design, synthesis, and identification of an orally active lead compound
1个月前
已完结
Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
3个月前
已完结
Cdk1 is sufficient to drive the mammalian cell cycle
3个月前
已完结
PROactively TACkling CDK4/6 therapy resistance
3个月前
已完结
CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest
3个月前
已完结
Treating cancer with selective CDK4/6 inhibitors
3个月前
已完结
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
3个月前
已完结
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
3个月前
已完结
Cell cycle, CDKs and cancer: a changing paradigm
3个月前
已完结
皖公网安备34019202002308
